Ki Back Chu

Dr. Ki Back Chu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
Ilaria RubinoIlaria Rubino
Ilaria Rubino
SHSumin Han
Sumin Han
EOEuna Oh
Euna Oh
SKSurjith Kumaran
Surjith Kumaran
MLMatthew Lawson
Matthew Lawson
Hyo-Jick ChoiHyo-Jick Choi
Hyo-Jick Choi

30 October 2023 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
HKHae-Ji Kang
Hae-Ji Kang
JLJiaoyang Li
Jiaoyang Li
ARAbdur Razzak
Abdur Razzak
GEGi-Deok Eom
Gi-Deok Eom
KYKeon-Woong Yoon
Keon-Woong Yoon
FQFu-Shi Quan
Fu-Shi Quan

7 January 2022 in ACS Infectious Diseases
Verified
Journal Article
Closed access
KCKi Back Chu
Ki Back Chu
HLHae-Ahm Lee
Hae-Ahm Lee
MPMarc Pflieger
Marc Pflieger
FFFabian Fischer
Fabian Fischer
YAYodita Asfaha
Yodita Asfaha
FQFu-Shi Quan
Fu-Shi Quan

28 November 2023 in ACS Infectious Diseases
Verified
Journal Article
Closed access
KYKeon-Woong Yoon
Keon-Woong Yoon
KCKi Back Chu
Ki Back Chu
GEGi-Deok Eom
Gi-Deok Eom
JMJie Mao
Jie Mao
MKMin-Ju Kim
Min-Ju Kim
FQFu-Shi Quan
Fu-Shi Quan

21 August 2023 in Parasites, Hosts and Diseases
Verified
Journal Article
Open access
PDF file
KCKi Back Chu
Ki Back Chu
FQFu-Shi Quan
Fu-Shi Quan
Toxoplasma gondii is an intracellular parasitic organism affecting all warm-blooded vertebrates. Due to the unavailability of commercialized human T. gondii vaccine, many studies have been reported investigating the protective efficacy of pre-clinical T. gondii vaccines expressing diverse antigens. Careful antigen selection and implementing multifarious immunization strategies could enhance protection against toxoplasmosis in animal models. Although none of the available vaccines could remove the tissue-dwelling parasites from the host organism, findings from these pre-clinical toxoplasmosis vaccine studies highlighted their developmental potential and provided insights into rational vaccine design. We herein explored the progress of T. gondii vaccine development using DNA, protein subunit, and virus-like particle vaccine platforms. Specifically, we summarized the findings from the pre-clinical toxoplasmosis vaccine studies involving T. gondii challenge infection in mice published in the past 5 years.

28 November 2023 in Parasites, Hosts and Diseases
Verified
Journal Article
Open access
PDF file
HKHae-Ji Kang
Hae-Ji Kang
JMJIE MAO
JIE MAO
MKMin-Ju Kim
Min-Ju Kim
KYKeon-Woong Yoon
Keon-Woong Yoon
GEGi-Deok Eom
Gi-Deok Eom
FQFu-Shi Quan
Fu-Shi Quan
Toxoplasma gondii infections are primarily diagnosed by serological assays, whereas molecular and fluorescence-based techniques are garnering attention for their high sensitivity in detecting these infections. Nevertheless, each detection method has its limitations. The toxoplasmosis detection capabilities of most of the currently available methods have not been evaluated under identical experimental conditions. This study aimed to assess the diagnostic potential of enzyme-linked immunosorbent assay (ELISA), real-time polymerase chain reaction (RT-PCR), immunohistochemistry (IHC), and immunofluorescence (IF) in BALB/c mice experimentally infected with various doses of T. gondii ME49. The detection of toxoplasmosis from sera and brain tissues was markedly enhanced in mice subjected to high infection doses (200 and 300 cysts) compared to those subjected to lower doses (10 and 50 cysts) for all the detection methods. Additionally, increased B1 gene expression levels and cyst sizes were observed in the brain tissues of the mice. Importantly, IHC, IF, and ELISA, but not RT-PCR, successfully detected T. gondii infections at the lowest infection dose (10 cysts) in the brain. These findings may prove beneficial while designing experimental methodologies for detecting T. gondii infections in mice.